71 related articles for article (PubMed ID: 27393729)
1. Relative Added Value: What are the Tools to Evalue it?
Jeunne CL; Woronoff-Lemsi MC; David N; Sahb Rd;
Therapie; 2008; 63(2):113-7. PubMed ID: 27393729
[TBL] [Abstract][Full Text] [Related]
2. Relative added value: what are the tools to evaluate it?
Le Jeunne C; Woronoff-Lemsi MC; David N; de Sahb R;
Therapie; 2008; 63(2):113-7, 107-11. PubMed ID: 18561884
[TBL] [Abstract][Full Text] [Related]
3. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
4. Value of post-registration studies for reimbursement renewal.
Molimard M; Bamberger M; Vray M
Therapie; 2009; 64(3):203-13. PubMed ID: 19671433
[TBL] [Abstract][Full Text] [Related]
5. [Assessment of actual benefits of new drugs by the Transparency Committee].
Le Jeunne C
J Fr Ophtalmol; 2008 Jan; 31(1):90-3. PubMed ID: 18401307
[TBL] [Abstract][Full Text] [Related]
6. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
Allen D; Rixson L
Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
[TBL] [Abstract][Full Text] [Related]
7. [Quantification of pharmacological progress by the French National Health Authorities].
Bouvenot G
Bull Acad Natl Med; 2006; 190(4-5):893-903; discussion 903-4. PubMed ID: 17195614
[TBL] [Abstract][Full Text] [Related]
8. [Drug evaluation by the French National Health Authority for reimbursement decisions].
Bouvenot G
Bull Acad Natl Med; 2005 Nov; 189(8):1683-90; discussion 1690-1. PubMed ID: 16737094
[TBL] [Abstract][Full Text] [Related]
9. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
10. [A proposal for reforming psychologists' training in France and in the European Union].
Bouchard JP
Encephale; 2009 Feb; 35(1):18-24. PubMed ID: 19250989
[TBL] [Abstract][Full Text] [Related]
11. [Most innovative drugs labelled during the last years in paediatrics: does the paediatrician have the tools for their identification?].
Autret-Leca E
Arch Pediatr; 2010 Aug; 17(8):1237-42. PubMed ID: 20615673
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of drug efficacy].
Massol J; Le Jeunne C
Presse Med; 2007 Mar; 36(3 Pt 2):505-11. PubMed ID: 17270386
[TBL] [Abstract][Full Text] [Related]
13. [The benefit provided by new medicinal products in 2005-2006--the viewpoint of the French National Authority for Health].
Bouvenot G
Therapie; 2007; 62(5):387-91. PubMed ID: 18206101
[TBL] [Abstract][Full Text] [Related]
14. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
15. Medico-economic evaluation of health products in the context of the Social Security Financing Act for 2012.
Dervaux B; Baseilhac E; Fagon JY; ; Ameye V; Angot P; Audry A; Becquemont L; Borel T; Cazeneuve B; Courtois J; Detournay B; Favre P; Granger M; Josseran A; Lassale C; Louvet O; Pinson J; de Pouvourville G; Rochaix L; Rumeau-Pichon C; de Saab R; Schwarzinger M; Sun A
Therapie; 2013; 68(4):253-63. PubMed ID: 23981264
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of the medical value of a drug. A necessity for the Transparency Commission].
Avouac B
Therapie; 1992; 47(1):9-16. PubMed ID: 1523604
[TBL] [Abstract][Full Text] [Related]
17. Assessing cancer drugs for reimbursement: methodology, relationship between effect size and medical need.
de Sahb-Berkovitch R; Woronoff-Lemsi MC; Molimard M;
Therapie; 2010; 65(4):373-7, 367-72. PubMed ID: 20854761
[TBL] [Abstract][Full Text] [Related]
18. How to improve the clinical development paradigm and its division into phases I, II and III.
Bamberger M; Moore N; Lechat P;
Therapie; 2011; 66(4):331-4, 327-30. PubMed ID: 21851796
[TBL] [Abstract][Full Text] [Related]
19. What criteria for pharmaceuticals reimbursement? An empirical analysis of the evaluation of "medical service rendered" by reimbursable drugs in France.
Le Pen C; Priol G; Lilliu H
Eur J Health Econ; 2003; 4(1):30-6. PubMed ID: 15609166
[TBL] [Abstract][Full Text] [Related]
20. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
